Cartesian Therapeutics【RNAC】銘柄情報

Cartesian Therapeutics Inc (RNAC) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

9.63

( -2.53% )

買値

7.37

売値

12.31

出来高

354,834

9.45 日の範囲 10.39

5.60 52 週間の範囲 15.57

時価総額

282.944M

前日終値

9.88

始値

10.10

時刻

9.64

最終取引時間

財務取引量

US$ 3,486,877

VWAP

9.8268

平均取引量 (3 か月)

US$ 245,449

発行済株式数

29,381,514

配当利回り

PER

-1.64

1 株当たり利益 (EPS)

-5.79

歳入

1.78M

純利益

-151.77M

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell matu... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.cartesiantherapeutics.com

本社

Frederick, United States

設立

Cartesian Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker RNAC. The last closing price for Cartesian Therapeutics was US$9.88. Over the last year, Cartesian Therapeutics shares have traded in a share price range of US$ 5.60 to US$ 15.57.

Cartesian Therapeutics currently has 29,381,514 shares in issue. The market capitalisation of Cartesian Therapeutics is US$282.94 million. Cartesian Therapeutics has a price to earnings ratio (PE ratio) of -1.64.

Form 8-K - Current report

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from...

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”...

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.21	29.7843665768	7.42	10.59	7.195	523765	9.15918977	CS
4	3.21	50	6.42	10.59	5.77	463096	7.50978064	CS
12	3.46	56.0777957861	6.17	10.59	5.6	269489	7.21568075	CS
26	2.13	28.4	7.5	10.59	5.6	226970	7.40313112	CS
52	-0.19	-1.93482688391	9.82	15.57	5.6	166323	7.9995189	CS
156	8.8235	1094.0483571	0.8065	41.87	0.4711	241536	6.38160826	CS
260	8.8235	1094.0483571	0.8065	41.87	0.4711	241536	6.38160826	CS

RNAC - Frequently Asked Questions (FAQ)

What is the current Cartesian Therapeutics Inc share price?

The current share price of Cartesian Therapeutics Inc is US$ 9.63

How many Cartesian Therapeutics Inc shares are in issue?

Cartesian Therapeutics Inc has 29,381,514 shares in issue

What is the market cap of Cartesian Therapeutics Inc?

The market capitalisation of Cartesian Therapeutics Inc is USD 282.94M

What is the 1 year trading range for Cartesian Therapeutics Inc share price?

Cartesian Therapeutics Inc has traded in the range of US$ 5.60 to US$ 15.57 during the past year

What is the PE ratio of Cartesian Therapeutics Inc?

The price to earnings ratio of Cartesian Therapeutics Inc is -1.64

What is the cash to sales ratio of Cartesian Therapeutics Inc?

The cash to sales ratio of Cartesian Therapeutics Inc is 157.42

What is the registered address of Cartesian Therapeutics Inc?

The registered address for Cartesian Therapeutics Inc is 7495 New Horizon Way, Frederick, Maryland, 21703

What is the Cartesian Therapeutics Inc website address?

The website address for Cartesian Therapeutics Inc is www.cartesiantherapeutics.com

Which industry sector does Cartesian Therapeutics Inc operate in?

Cartesian Therapeutics Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Cartesian Therapeutics Inc について

RNAC 最新ニュース

Form 8-K - Current report

Cartesian Therapeutics Announces New Employment Inducement Grant

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Form 8-K - Current report

Cartesian Therapeutics Announces New Employment Inducement Grant

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Announces New Employment Inducement Grants

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

RNAC - Frequently Asked Questions (FAQ)

RNAC 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する